Publisher’s Update – April 2026 This article was originally published in 2015 and remains a helpful overview for newly diagnosed PV patients. One important treatment update: since publication, the FDA has approved Besremi (ropeginterferon alfa-2b) for polycythemia vera. Besremi is a next-generation, long-acting interferon administered every two weeks and is the first interferon specifically FDA-approved […]
MPD-RC 111 Clinical Trial for High Risk Polycythemia Vera or Essential Thrombocythemia
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses the Myeloproliferative Disorders Research Consortium (MPD-RC 111), a clinical trial investigating single arm salvage therapy with pegylated interferon alfa-2a for patients with high risk polycythemia vera or high risk essential […]
MPD-RC 112 Clinical Trial for High Risk PV and ET Patients
Randomized Clinical Trial of Pegylated Interferon alfa-2a versus Hydroxyurea Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Key Points: Why are we doing the Study? Top […]
